Cytophage Technologies

Cytophage Technologies is a Canadian biotechnology firm specializing in the development of bacteriophage-based solutions aimed at combating bacterial infections that affect human and animal health, as well as food security. It is the first phage company to go public in Canada and uses advanced molecular genetic techniques and synthetic biology to produce highly specific bacteriophages.

Its animal-health portfolio includes AviPhage, a product for addressing Salmonella and E.Coli in poultry. Its benefits include enhancement of animal and gut health and reduction of mortality risk and bacteria levels. Furthermore, the company had plans to launch BoviPhage, a bovine mastitis product, and OvaPhage, a product that targets Salmonella, Escherichia, and Shigella on the surface of eggs.

The company had begun construction of a 20,000-foot facility, housing a state-of-the-art laboratory, GMP-certified manufacturing suite, administrative offices, and warehouse space, which was slated to open in June 2024.

Key customers and partnerships

In 2024, the company entered a distribution agreement with Renata Limited-Animal Health

Division in Dhaka, Bangladesh to distribute Cytophage’s animal health products in Bangladesh, Myanmar, Nepal, and Sri Lanka.

Funding and financials

In February 2024, the company went public on the TSX Venture Exchange under the ticket CYTO.